Pamela L. Kunz, MD, Yale School of Medicine

Articles

NETs Management: Unmet Needs and Future Direction

June 19th 2020

NETs Data Updates at ASCO 2020

June 19th 2020

NETTER-1 Clinical Trial Overview

June 19th 2020

Subcutaneous Pen Formulation FDA Approval

June 19th 2020

Inoperable NETs: The Role of Systemic Therapy

June 19th 2020

New Biomarkers for Diagnosis and Prognosis

June 19th 2020

Optimal Sequencing Strategy for NETs

June 19th 2020

NETs Treatment Landscape and Selection Factors

June 19th 2020

Dr. Kunz on the CLARINET Study for GEP-NETs

January 26th 2016

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses tumor response in the CLARINET study, which examined lanreotide depot versus placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors

October 17th 2015

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Kunz on Anticipated Trial Results for Patients with Neuroendocrine and Carcinoid Tumors

March 4th 2015

Pamela L. Kunz, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses some anticipated trial results for patients with neuroendocrine and carcinoid tumors.

Dr. Kunz on Sequencing Agents for Pancreatic NETs

October 10th 2014

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

Dr. Kunz on Identifying Gastric Cancer Subtypes

April 23rd 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the effort to identify molecular subtypes of gastric cancer.

Dr. Kunz on Treatment Options for Pancreatic NETs

February 10th 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses current and future treatment options for patients with neuroendocrine tumors (NETs).